Ulrike Nitz

Deutsches Archäologisches Institut, Zentrale

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 3 papers. Top paper: “TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy”.

TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy

Annals of Oncology(2024)10.1016/j.annonc.2024.10.012

N/A

0.533DataRank · unranked

34 citations

S.R. Stecklein, Oleg Gluz, Guillermo Villacampa, Marı́a del Monte-Millán, Ulrike Nitz +42 more

HER2-low status as a distinct breast cancer subtype: myth or truth? Analysis of the WSG trials WSG-ADAPT-HR+/HER2-, WSG-PlanB, and WSG-ADAPT-TN

Breast Cancer Research(2025)10.1186/s13058-025-01969-z

N/A

0.388DataRank · unranked

8 citations

Oleg Gluz, Matthias Christgen, Mattea Reinisch, Sherko Kümmel, Ulrike Nitz +25 more

Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials

The Lancet(2023)10.1016/s0140-6736(23)00285-4

N/A

0DataRank · unranked

195 citations

Rosie Bradley, Richard Gray, Robert K. Hills, Hongchao Pan, Richárd Pető +95 more